LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Clotting Causes Significant Mortality in COVID-19 Patients

By LabMedica International staff writers
Posted on 11 May 2020
Print article
Image: The ACL Top 550 hemostasis analyzer (Photo courtesy of Werfen).
Image: The ACL Top 550 hemostasis analyzer (Photo courtesy of Werfen).
Although the underlying pulmonary pathophysiology remains incompletely understood, severe COVID-19 infection is associated with a marked alveolar inflammatory cell infiltrate, together with a systemic cytokine storm response.

Consistent with the hypothesis that coagulation activation may play a role in COVID-19 pathogenesis, post-mortem studies have highlighted marked pathological changes specifically involving the lung microvasculature, including disseminated micro-thrombi and significant hemorrhagic necrosis.

Clinical scientists collaborating with those at the Royal College of Surgeons University of Medicine and Health Sciences (Dublin, Ireland) recruited consecutive adult patients with COVID-19 from March 13th to April 10th 2020. Hemostasis assays were performed including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, and D-dimer levels. The PT, APTT and Fibrinogen assays were measured on the ACL Top 550 analyzer (Werfen, Barcelona, Spain).

Coagulation testing performed on admission in the total cohort demonstrated normal PT and APTT. In contrast, plasma D-dimer levels were significantly increased (median 732; range 200 to 10,000 ng/mL). D-dimer levels were above the normal range in 67% of the total cohort on admission. Fibrinogen levels were significantly increased (median 4.7; range 3.0 to 9.9 g/L) on admission, with levels remaining persistently elevated throughout hospitalization. The team noted that that they had found that abnormal blood clotting occurring in Irish patients with severe COVID-19 infection, causing micro-clots within the lungs. They also found that Irish patients with higher levels of blood clotting activity had a significantly worse prognosis and were more likely to require ICU admission.

James S. O'Donnell, a Professor and Consultant Hematologist and senior author of the study, said, “Our novel findings demonstrate that COVID-19 is associated with a unique type of blood clotting disorder that is primarily focused within the lungs and which undoubtedly contributes to the high levels of mortality being seen in patients with COVID-19. In addition to pneumonia affecting the small air sacs within the lungs, we are also finding hundreds of small blood clots throughout the lungs. This scenario is not seen with other types of lung infection, and explains why blood oxygen levels fall dramatically in severe COVID-19 infection. Understanding how these micro-clots are being formed within the lung is critical so that we can develop more effective treatments for our patients, particularly those in high risk groups.” The study was published on April 24, 2020 in the British Journal of Haematology.

Related Links:
Royal College of Surgeons University of Medicine and Health Sciences
Werfen


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.